Trial Profile
Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alefacept (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Astellas Pharma US
- 09 Mar 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 09 Mar 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 09 Mar 2012 Actual patient number is 3 according to ClinicalTrials.gov.